Cell Expansion Global Market Report 2024

The global cell expansion market has grown rapidly in recent years. It will grow from $24.65 billion in 2023 to $28.25 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth observed in the historical period can be attributed to several factors, including increased public awareness and acceptance, the expanding applications of cell-based research, a rising demand for cell-based therapies, growth in the biopharmaceutical industry, and advancements in regenerative medicine. These factors collectively contributed to the expansion witnessed during that timeframe.

The global cell expansion market is expected to see rapid growth in the next few years. It will grow to $50.39 billion in 2028 at a compound annual growth rate (CAGR) of 15.6%. The anticipated growth in the forecast period can be attributed to increasing investments in biotechnology, the expansion of stem cell research, growth in clinical trials and drug development activities, a growing demand for personalized medicine, and the establishment of biobanking and cell repositories. Significant trends expected in the forecast period encompass continuous technological advancements, innovative product developments, and strategic collaborations within the industry. These trends collectively contribute to the projected growth in the upcoming period.

The anticipated increase in chronic diseases is set to drive the demand for the cell expansion market. Chronic diseases, characterized by long-lasting illnesses that are often incurable but occasionally controllable, are on the rise due to factors such as increased tobacco product usage, poor nutrition, physical inactivity, and excessive alcohol consumption. Cell expansion becomes crucial in replenishing nutrients while preventing the accumulation of toxic waste products, which could hinder culture performance. As projected by the National Center for Biotechnology Information (NCBI) in January 2023, the number of individuals aged 50 years and above with at least one chronic illness is expected to surge by 99.5% by the year 2050, reaching 142.66 million from 71.522 million in 2020. This surge in chronic diseases is a significant driver for the growth of the cell expansion market.

The growth of the cell expansion market is expected to be propelled by increasing government funding for research and development. Government funding plays a crucial role in fostering innovation, advancing cell-based therapies, and accelerating progress in regenerative medicine. An illustrative example is the National Cancer Institute, a US-based government agency, which received a budget of $7.3 billion in fiscal year 2023 from the United States Congress, marking a $408 million increase from 2022. This substantial increase in government funding for research and development is a driving force behind the growth of the cell expansion market.

Technological advancement is emerging as a key trend in the cell expansion market, with major players focusing on innovative technologies to meet specific needs and specialized research applications. For instance, in December 2021, Novartis, a US-based pharmaceutical company, introduced T-Charge, a next-generation CAR-T platform with first-in-human data. T-Charge enables CAR-T cell expansion primarily within a patient's body, eliminating the need for extended culture time outside the body. This innovative platform offers better and more durable responses, improved long-term outcomes, and a reduced risk of severe adverse events.

Major companies in the cell expansion market are intensifying their focus on introducing advanced bioprocessing platforms, such as the Quantum Flex Cell Expansion System, to gain a competitive edge. The Quantum Flex Cell Expansion System, launched by Terumo Blood and Cell Technologies in June 2023, is designed for scalable and flexible expansion of cell therapies, providing efficient and controlled manufacturing capabilities for cell-based medical treatments. This system supports the expansion of various applications, including suspension and adherent cells, viral vectors, and exosome production, offering the necessary flexibility, scalability, and connectivity to support the growth of cell therapies.

In a strategic move, Sartorius AG, a Germany-based pharmaceutical company, acquired Polyplus-Transfection SA for $2.36 billion in March 2023. This acquisition positions Sartorius AG to strengthen its supply of cell and gene therapy solutions, expanding its portfolio for gene therapies and gene-modified cell therapies. Polyplus-Transfection SA, based in France, is a biotechnology company supporting gene and cell therapy, biologics manufacturing, and life science research.

Major companies operating in the cell expansion market report are Thermo Fisher Scientific Inc., Becton Dickinson and Company, Lonza Group, Corning Inc., Merck KGaA, Sartorius Stedim Biotech SA, Terumo Corporation, Miltenyi Biotec GmbH, Danaher Corporation, Stemcell Technologies Inc., Beckman Coulter Inc., Takara Bio Inc., RepliCel Life Sciences, Neximmune Inc., Celltainer Biotech BV, GE HealthCare Technologies Inc., ReproCELL USA Inc., iXCells Biotechnologies Inc., Neuromics LLC, G&G Technologies Inc., Eppendorf AG, Avantor Inc., Bio-Techne Corporation, BioLife Solutions Inc., Cesca Therapeutics Inc., Core Dynamics Ltd., Lifeline Scientific Inc., Princeton Cryotech Inc., VWR International LLC, Azenta US Inc., MVE Biological Solutions LLC, BioCision LLC, BioSpherix Ltd., and Worthington Industries Inc.

North America was the largest region in the cell expansion market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell expansion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell expansion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main categories of cell expansion include mammalian, microbial, and other types. Mammalian cell expansion involves the cultivation of cells derived from mammals, conducted through the in vitro cultivation of cells in flasks or bioreactors. The products associated with mammalian cell expansion encompass consumables, reagents, media, serums, disposables, and instruments. These products find application in various fields such as biopharmaceuticals, tissue culture and engineering, vaccine production, drug development, gene therapy, cancer research, stem cell research, and others. The end-users of mammalian cell expansion products include biopharmaceutical and biotechnology companies, research institutes, cell banks, and other relevant entities.

This report provides cell expansion market statistics, including cell expansion industry global market size, regional shares, competitors with a cell expansion market share, detailed cell expansion market segments, market trends and opportunities, and any further data you may need to thrive in the cell expansion industry. This cell expansion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell expansion market includes revenues earned by entities by providing bioreactors and automated cell expansion systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.